与HMGCR相关的SNP和胆病:他类药物可能会产生超出降脂效应的效应
1Department of Gastroenterology, China-Japan Friendship Hospital, No. 2 Yinghuayuan East Street, Chaoyang District, Beijing 100029, China.
Postgraduate medical journal
|December 11, 2025
概括
单类药物显著降低了胆结石的风险,独立于它们的降脂效应. 这项研究使用遗传变异来调查他类药物和胆病之间的因果关系,发现了保护性关联.
科学领域:
- 心血管药理学心血管药理学
- 遗传流行病学遗传流行病学
- 胃肠病学 胃肠病学
背景情况:
- 关于他类药物在预防胆结石中的作用有争议.
- 类药物是广泛使用的降脂药物.
- 了解他类药物和胆病之间的联系在临床上很重要.
研究的目的:
- 通过使用遗传变异来研究他类药物和胆病之间的因果关系.
- 探索是否降脂效应调解了他类药物和胆结石风险之间的关联.
- 为了检查其他降脂药物对胆病的影响.
主要方法:
- 使用药物向的门德尔随机化 (MR).
- 在HMGCR基因附近的单核酸多态 (SNP) 被用来模仿他类药物的效应.
- 两种样本的MR分析评估了脂质和其他降脂药物与胆病风险的关联.
主要成果:
- 通过与HMGCR相关的SNP模拟的他类药物与降低胆病风险相关 (OR 0.445).
- 埃泽胺和PCSK9抑制剂并没有显示出类似的胆病风险降低.
- 在多变量MR分析中,无论是LDL-C还是HDL-C水平都与胆病风险没有显著的关联.
结论:
- 类他类药物与降低胆病风险有关.
- 对于胆结石而言,他类药物的保护作用可能并非由其降脂能力介导.
- 需要进一步的研究来证实这些发现,并阐明潜在的机制.
相关概念视频
Lipid-Lowering Drugs: Statins and Miscellaneous Agents
1.3K
Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
1.3K
Cholesterol: Significance and Regulation
1.2K
Although not a source of energy, cholesterol plays a significant role as a foundational structure for bile salts, steroid hormones, and vitamin D, as well as being a crucial component of plasma membranes. Approximately 15% of blood cholesterol is derived from our diet, with the remainder synthesized from acetyl CoA by the liver and intestines. Cholesterol is eliminated from the body through its conversion into bile salts, which are eventually discarded in the feces.
Considering cholesterol and...
Considering cholesterol and...
1.2K
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
236
Hepatic impairment, characterized by decreased liver function, does not uniformly mandate adjustments in drug dosage. Whether dosage modifications are necessary depends on various factors related to the drug's metabolism and elimination pathways. If a drug is primarily excreted via the kidneys and bypasses significant hepatic processing, if it undergoes minimal metabolic transformation in the liver, or if it is volatile and primarily expelled through the lungs, dose adjustments may not be...
236
Atherosclerosis III: Management
293
Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
293
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
169
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
169
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
200
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
200


